FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210588695> ?p ?o ?g. }

• W4210588695 abstract "Platelet-derived growth subunit A (PDGFA) plays critical roles in development of glioblastoma (GBM) with substantial evidence from TCGA database analyses and in vivo mouse models. So far, only platelet-derived growth receptor α (PDGFRA) has been identified as receptor for PDGFA. However, PDGFA and PDGFRA are categorized into different molecular subtypes of GBM in TCGA_GBM database. Our data herein further showed that activity or expression deficiency of PDGFRA did not effectively block PDGFA activity. Therefore, PDGFRA might be not necessary for PDGFA function.To profile proteins involved in PDGFA function, we performed co-immunoprecipitation (Co-IP) and Mass Spectrum (MS) and delineated the network of PDGFA-associated proteins for the first time. Unexpectedly, the data showed that EPHA2 could be temporally activated by PDGFA even without activation of PDGFRA and AKT. Furthermore, MS, Co-IP, in vitro binding thermodynamics, and proximity ligation assay consistently proved the interaction of EPHA2 and PDGFA. In addition, we observed that high expression of EPHA2 leaded to upregulation of PDGF signaling targets in TCGA_GBM database and clinical GBM samples. Co-upregulation of PDGFRA and EPHA2 leaded to worse patient prognosis and poorer therapeutic effects than other contexts, which might arise from expression elevation of genes related with malignant molecular subtypes and invasive growth. Due to PDGFA-induced EPHA2 activation, blocking PDGFRA by inhibitor could not effectively suppress proliferation of GBM cells, but simultaneous inhibition of both EPHA2 and PDGFRA showed synergetic inhibitory effects on GBM cells in vitro and in vivo. Taken together, our study provided new insights on PDGFA function and revealed EPHA2 as a potential receptor of PDGFA. EPHA2 might contribute to PDGFA signaling transduction in combination with PDGFRA and mediate the resistance of GBM cells to PDGFRA inhibitor. Therefore, combination of inhibitors targeting PDGFRA and EHA2 represented a promising therapeutic strategy for GBM treatment." @default.
• W4210588695 created "2022-02-08" @default.
• W4210588695 creator A5002967869 @default.
• W4210588695 creator A5013049125 @default.
• W4210588695 creator A5015235892 @default.
• W4210588695 creator A5015946020 @default.
• W4210588695 creator A5018389594 @default.
• W4210588695 creator A5019839302 @default.
• W4210588695 creator A5021541475 @default.
• W4210588695 creator A5023751554 @default.
• W4210588695 creator A5025090000 @default.
• W4210588695 creator A5036054973 @default.
• W4210588695 creator A5038627852 @default.
• W4210588695 creator A5044205235 @default.
• W4210588695 creator A5059124207 @default.
• W4210588695 creator A5060142050 @default.
• W4210588695 creator A5061261246 @default.
• W4210588695 creator A5064776877 @default.
• W4210588695 creator A5069695401 @default.
• W4210588695 creator A5072208389 @default.
• W4210588695 creator A5072279163 @default.
• W4210588695 creator A5083122800 @default.
• W4210588695 creator A5087181844 @default.
• W4210588695 creator A5088637965 @default.
• W4210588695 creator A5090085226 @default.
• W4210588695 creator A5090875147 @default.
• W4210588695 date "2022-02-02" @default.
• W4210588695 modified "2023-10-15" @default.
• W4210588695 title "EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma" @default.
• W4210588695 cites W1534154320 @default.
• W4210588695 cites W1924902828 @default.
• W4210588695 cites W1931740967 @default.
• W4210588695 cites W1949731977 @default.
• W4210588695 cites W1960989553 @default.
• W4210588695 cites W1966311581 @default.
• W4210588695 cites W197014098 @default.
• W4210588695 cites W1977260182 @default.
• W4210588695 cites W1981637202 @default.
• W4210588695 cites W1997670728 @default.
• W4210588695 cites W2003516811 @default.
• W4210588695 cites W2009149174 @default.
• W4210588695 cites W2010093984 @default.
• W4210588695 cites W2025183726 @default.
• W4210588695 cites W2025739022 @default.
• W4210588695 cites W2040458067 @default.
• W4210588695 cites W2040574920 @default.
• W4210588695 cites W2042258261 @default.
• W4210588695 cites W2051450173 @default.
• W4210588695 cites W2052038529 @default.
• W4210588695 cites W2055475004 @default.
• W4210588695 cites W2080611906 @default.
• W4210588695 cites W2092956762 @default.
• W4210588695 cites W2093486460 @default.
• W4210588695 cites W2096287682 @default.
• W4210588695 cites W2104607769 @default.
• W4210588695 cites W2105528101 @default.
• W4210588695 cites W2106757173 @default.
• W4210588695 cites W2119748249 @default.
• W4210588695 cites W2123106337 @default.
• W4210588695 cites W2125378172 @default.
• W4210588695 cites W2130410032 @default.
• W4210588695 cites W2130511906 @default.
• W4210588695 cites W2131884474 @default.
• W4210588695 cites W2135823227 @default.
• W4210588695 cites W2139429540 @default.
• W4210588695 cites W2145897029 @default.
• W4210588695 cites W2148977460 @default.
• W4210588695 cites W2158681922 @default.
• W4210588695 cites W2161289668 @default.
• W4210588695 cites W2163440976 @default.
• W4210588695 cites W2165871546 @default.
• W4210588695 cites W2168055604 @default.
• W4210588695 cites W2169743030 @default.
• W4210588695 cites W2346627954 @default.
• W4210588695 cites W2366536035 @default.
• W4210588695 cites W2587964111 @default.
• W4210588695 cites W2727830163 @default.
• W4210588695 cites W2797587294 @default.
• W4210588695 cites W2801958156 @default.
• W4210588695 cites W2805955117 @default.
• W4210588695 cites W2810882198 @default.
• W4210588695 cites W2886862207 @default.
• W4210588695 cites W2890374908 @default.
• W4210588695 cites W2926233720 @default.
• W4210588695 cites W2969358228 @default.
• W4210588695 cites W3005987282 @default.
• W4210588695 cites W3208354674 @default.
• W4210588695 cites W4200418957 @default.
• W4210588695 cites W4234865248 @default.
• W4210588695 doi "https://doi.org/10.1038/s41392-021-00855-2" @default.
• W4210588695 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35105853" @default.
• W4210588695 hasPublicationYear "2022" @default.
• W4210588695 type Work @default.
• W4210588695 citedByCount "7" @default.
• W4210588695 countsByYear W42105886952022 @default.
• W4210588695 countsByYear W42105886952023 @default.
• W4210588695 crossrefType "journal-article" @default.
• W4210588695 hasAuthorship W4210588695A5002967869 @default.
• W4210588695 hasAuthorship W4210588695A5013049125 @default.
• W4210588695 hasAuthorship W4210588695A5015235892 @default.

• next